| Nov 18 |
Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study
|
| Nov 11 |
DWTX: Phase 2 Long COVID Results Expected Soon
|
| Nov 11 |
Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
|
| Nov 8 |
Q3 2024 Dogwood Therapeutics Inc Earnings Call
|
| Nov 8 |
Dogwood Therapeutics Inc (DWTX) Q3 2024 Earnings Call Highlights: Strategic Financing and ...
|
| Nov 7 |
Virios Therapeutics GAAP EPS of -$2.05
|
| Nov 7 |
Dogwood Therapeutics Announces Third Quarter 2024 Financial Results
|
| Oct 31 |
Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024
|
| Oct 30 |
Dogwood Therapeutics regains compliance with Nasdaq's minimum bid price rule
|
| Oct 30 |
Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
